The European Commission has approved Sobi’s long-acting factor VIII replacement therapy Altuvoct for the treatment of haemophilia A in the EU, with a broad label that spans all ages and any
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
